ACADIA Pharmaceuticals (ACAD)
(Delayed Data from NSDQ)
$18.75 USD
-0.39 (-2.04%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $18.76 +0.01 (0.05%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth F Momentum B VGM
Brokerage Reports
0 items in cart
ACADIA Pharmaceuticals Inc. [ACAD]
Reports for Purchase
Showing records 161 - 180 ( 246 total )
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
We are resuming coverage of Acadia with a Neutral rating and $28 PT.
Provider: Roth Capital Partners, Inc.
Analyst: HIGGINS M
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Notes from Management Meeting: With Limited Visibility on Launch Until 2017, We Look to Areas for Expansion for NUPLAZID
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Proprietary Survey of 100 Physicians Points to Nuplazid Bullishness: Reit Buy and Raising PT to $60
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
After Changes Upon Changes, Things Are More or Less the Same; Reit Buy and $50PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Remain Confident that Clinical Benefits Outweigh Risks Following Release of Briefing Documents; Reit Buy and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Points of Focus at the Upcoming AdCom Panel: Reiterate Buy Rating and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Wharton Healthcare Business Conference Recap: The Innovation Game
Provider: Rodman & Renshaw, Co.
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
2016 Healthcare Sector Outlook: Year Ahead Perspectives
Provider: Rodman & Renshaw, Co.
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
2016 Healthcare Sector Outlook: Year Ahead Perspectives
Provider: H.C. Wainwright & Co., Inc.
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Neuropsychiatric Symptoms in Alzheimer?s Disease: Clinical Trial Challenges
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Our Thoughts on a Potential AdCom Timetable and Nuplazid Indication Expansion
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Opportunities for Label and Indication Expansion Beyond PDP; Reit Buy and $50 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Snakes and Ladders: Nuplazid on Track for Regulatory Review in 2H15
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
Neurologists? Feedback on Parkinson?s Disease Psychosis
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
An Episode of Brief and Transient Agitation/Aggression
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A
Company: ACADIA Pharmaceuticals Inc.
Industry: Medical - Biomedical and Genetics
From the Academic?s Couch: An Analysis of Atypical Antipsychotics in AD+P and PD+P; Reit Buy and $50 PT
Provider: H.C. WAINWRIGHT & CO., INC.
Analyst: FEIN A